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Puromycin aminonucleoside (PAN)-induced nephrosis is a
well-described model of human idiopathic nephrotic syndrome,
but the mechanism of PAN's effect is not completely under-
stood. To investigate whether proteinuria in the PAN model
is associated with an alteration of zonula occludens-1 (ZO-1)
expression within the glomeruli, and whether cyclosporin A
(CsA) has an effect on proteinuria and ZO-1 expression in this
model, eighteen Sprague Dawley (SD) rats were assigned into
three groups. Twelve rats received a single intraperitoneal
injection of PAN (15 mg/100 g). The other six rats received
an equal volume of saline (normal control group; control). CsA
solution was administered intraperitoneally once a day for 20
days after the PAN injection (n=6, PAN+CsA). The remaining
six rats received PAN, but they didn't receive CsA (n=6,
PAN). Compared to control rats (35.1 ± 5.4 mg/day), the
24-hour urinary protein excretion on day 18 was significantly
higher in the PAN rats (1021.9 ± 128.9 mg/day, p<0.01), and
the CsA treatment partly reversed the increase in proteinuria
in the PAN rats (556.4 ± 102.3 mg/day, p<0.05). Glomerular
ZO-1 protein expressions were significantly increased in the
PAN rats as compared to the control group on day 20 (176%,
p<0.01). CsA treatment for 20 days in the PAN rats inhibited
the increase in ZO-1 protein expression by 71.1% (p<0.05).
CsA treatment significantly diminished the glomerular ZO-1
expression in the PAN rats as assessed by immunohisto-
chemistry. CsA treatment significantly reduced proteinuria and
the diminished glomerular ZO-1 expression in a PAN ne-
phrosis rat model. These findings suggest the potential role of
the slit diaphragm associated proteins in the development of
the nephrotic syndrome, and CsA decreased the proteinuria
probably by a direct action on the expression of these proteins
in podocytes. Further investigations are needed to clarify the
role of slit diaphragm associated proteins in the development
of PAN nephrosis.
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INTRODUCTION
The retraction of the podocyte foot processes
into their cell bodies and spacing-out of the filtra-
tion slits constitute the hallmark ultrastructural
changes seen in the minimal change nephrotic
syndrome for humans and for the corresponding
rat models.
1-3 Proteinuria associated with glome-
rular diseases is secondary to alterations of the
charge-selective and/or size-selective properties
of the GBM, but molecular modifications that are
responsible for these functional changes are still
poorly understood.
4 Although the role of the glo-
merular basement membrane (GBM) for restric-
ting the filtration of macromolecules has been
emphasized for nearly two decades,
1,5 several
recent studies have shown that slit diaphragms
located between the foot processes may play a cri-
tical role as barriers to retain macromolecules.
6-10
Pavenstadt et al.
11 proposed several physiologic
functions of podocyte: First, they function as a
specific pericyte counteracting the high transmu-
ral distending forces to permit the high-pressure
perfusion of glomerular capillaries. Second, podo-
cytes are crucially involved in establishing the
specific permeability properties of the glomerular
filter. Third, podocytes are responsible for the
continuous cleaning of the filter. Yet there was no
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direct evidence offered for supporting these
hypotheses. Puromycin aminonucleoside (PAN)-
induced nephrosis is a well-described model of
human idiopathic nephrotic syndrome, but the
mechanism of PAN's effect is not completely un-
derstood. Smithies
12 has recently emphasized that
the single nephron glomerular filtration rate (GFR)
is a prime factor in determining the development
of proteinuria. He thought that severe pathologi-
cal decreases in the slit diaphragm length seen in
minimal-change nephrotic syndrome for humans
and for animals treated with puromycin aminonu-
cleoside, or for humans or animals with mutations
in the gene coding for nephrin, can cause albumi-
nuria by the reduction of the single nephron GFR.
In recent years, several molecules have been
reported to be associated with the slit diaph-
ragm
13-16. Zonula occludens-1 (ZO-1), which is a
protein found on the cytoplasmic face of tight
junctions, is also expressed on the cytoplasmic
surface of podocyte foot processes at the point of
insertion of the slit diaphragm13. Several reports
showed that the change of ZO-1 distribution and/
or its expression in podocytes is related with pro-
teinuria.
10,17,18 Kawachi's experiments
10 demonstr-
ated that monoclonal antibody 5-1-6 alters the ex-
pression of both nephrin and ZO-1 proteins in rat
podocytes. Although Kurihara et al.
18 described
the altered ZO-1 protein distribution in podocytes
of a PAN treated rat model, they did not show the
quantitative change of ZO-1 protein expression.
The antiproteinuric effect of cyclosporin A
(CsA) has been reported in several human and
animal studies. In both children and adults,
19-21
CsA is an option for those who have not re-
sponded to conventional steroid treatment. The
pharmacological antiproteinuric effect of CsA has
long been demonstrated both experimentally and
clinically. Meyrier
22 already stressed that the
mode of action of CsA in reducing or suppressing
proteinuria in glomerular diseases is not merely
linked to its immunosuppressive virtues. In fact,
several lines of evidence, both from experimental
evidence and in human studies, have led to the
belief that CsA exerts a non-immunologic, anti-
proteinuric effect of its own. Jameson et al.
23 have
demonstrated a marked effect of CsA on the glo-
merular filtration barrier that was independent of
renal perfusion in a study of filtration by glo-
meruli isolated from Wistar-Kyoto rats. Zietse et
al.
24 have shown that CsA induced complete or
partial remissions in patients with various ne-
phrotic syndromes, with no consistent change
being noted for the GFR. Kokui et al.
25 have
reported that CsA can reduce proteinuria for rats
with PAN nephrosis, but CsA cannot ameliorate
the glomerular changes seen upon examination
with a conventional light microscope. Recently,
Luimula et al.
26 have shown an alteration of pro-
tein levels for several podocyte associated mole-
cules in PAN induced nephrosis of rats, and these
alterations seem to be associated with the devel-
opment of a proteinuria, but there has been no
report on the effect of CsA on the podocyte-
associated molecules in PAN nephrosis.
In this study, we have adopted a PAN-induced
rat model nephrosis that represents a minimal
change nephrotic syndrome in humans, and we
investigated whether proteinuria is associated
with alteration of ZO-1 expression within the
glomeruli, and whether CsA diminished protein-
uria and ZO-1 protein expression.
MATERIALS AND METHODS
Experimental group models
Eighteen male Sprague-Dawley rats (150 to 200
g) were used in this study. The animals were
treated according to the rules and regulations of
the Ethical Committee of the Yonsei University.
The rats were fed standard rat chow and they had
a free access to tap water. Twelve rats received a
single intraperitoneal injection of PAN (15 mg/
100 g; Sigma-Aldrich Co., St. Louis, MO, U.S.A.),
which was dissolved in saline at a dilution of 20
mg/ml. The other six rats received an equal vol-
ume of saline (normal control group; control).
From the day of PAN injection (Day 0), CsA solu-
tion for intravenous use (Chongkundang Pharma-
ceutical Corp., Seoul, Korea) was diluted 1 : 10
with saline and then administered intraperito-
neally once a day for 20 days (n=6, PAN+CsA).
The remaining six rats received PAN, but they
didn't receive CsA (n=6, nephrotic control rats;
PAN).
Urine was collected overnight from the meta-Cyclosporin Reduced ZO-1 Expression in PAN Rats 143
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bolic cages at days 0, 9 and 18 after the day of the
PAN injection. The urinary protein was measured
with a Bio-Rad protein assay kit (Bio-Rad Labo-
ratories, Inc., Hercules, CA, USA) and by using a
spectrophotometer. Serum creatinine was mea-
sured at 0 and 18 days after the PAN injection. At
the end of the study (20 days after the PAN
administration), the animals were sacrificed and
their kidneys were removed and then processed
for a Western blot procedure and immunohistche-
mistry.
Western blot analysis
Rat glomeruli were isolated by a sieving tech-
nique, and they were then lyzed in a sodium
dodecyl sulfate (SDS) sample buffer [2% SDS, 10
mmol/L Tris-HCl, pH 6.8, 10% (vol/vol) glyc-
erol]. The lysate mixture was centrifuged at 10,000
×g for 10 minutes at 4 , and the resultant super-
natant was stored at 70 . Protein concentrations
were determined with a Bio-Rad kit (Bio-Rad).
Aliquots of 50 g protein were treated with μ
Laemmli sample buffer, then heated at 95 for
five minutes and finally they were electropho-
resed at 50 g/lane in a 6% acrylamide dena μ -
turing SDS-polyacrylamide gel. The proteins were
next transferred to a Hybond-ECL membrane
(Amersham Life Science, Inc., Arlington Heights,
IL, U.S.A.) using a Bio-Rad semidry blotting appa-
ratus (Bio-Rad). The membrane was incubated in
a blocking buffer A [phosphate-buffered saline
(PBS), 0.1% Tween-20, and 5% nonfat milk] for
one hour at room temperature and then incubated
overnight at 4 with a rabbit polyclonal antibody
that was specifically reactive to the rat ZO-1. The
membrane was washed once for 15 minutes and
twice for five minutes in PBS with 0.1% Tween-20,
and then the membrane was incubated in buffer
A with horseradish peroxidase-linked sheep anti-
mouse IgG (Amersham) at a 1 : 1000 dilution. The
washes were repeated, and at last, the membrane
was developed with a chemiluminescent agent
(ECL; Amersham Life Science, Inc.).
Tissue processing and staining procedure
The renal tissue was fixed in 10% neutral-buf-
fered formalin and then processed in the stan-
dard manner; 5 m sections were utilized. The μ
slides were deparaffinized, hydrated in ethyl alco-
hol and then washed in tap water. Antigen re-
trieval was carried out in a 10 mmol/L sodium
citrate buffer for 20 minutes using a Black and
Decker vegetable steamer. For ZO-1 staining, a
polyclonal rabbit anti-rat ZO-1 antibody (Zymed
Laboratories, Inc., San Francisco, CA, U.S.A.) di-
luted to 1:200 with 2% casein in BSA was applied
for an overnight incubation at room temperature.
After washing, the biotinylated link anti-rabbit
IgG (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, U.S.A.) was added for 20 minutes. The slides
were washed and then incubated with a streptoa-
vidin-HRP (Santa Cruz) for 30 minutes. Diami-
nobenzidine was added for one minute and the
slides were counterstained with hematoxylin.
The assessment of glomerular ZO-1 immuno-
histochemical staining was scored on a semiquan-
titative scale of 0 to 4 according to staining inten-
sity that was compensated with the background
staning intensity. All glomeruli in each section
were examined by a pathologist blinded to the
identity of the groups, and a staining score was
obtained by multiplying the intensity of podocytes
staining by the percentage of glomeruli staining
for that intensity, these numbers were than added
for each experimental animal to give the staining
score. (intensity of staining) × (% of glomeruli
with that intensity)=staining score.
Statistical analysis
All values are expressed as the mean ± SEM.
Statistical analysis was performed using the
statistical package SPSS for Windows Version 11.0
(SPSS, Inc., Chicago, IL, USA). The results were
analyzed using a Student's t-test or the Kruskal-
Wallis nonparametric test for multiple com-
parisons.
RESULTS
Throughout the experiment, the rats' food and
water intake was similar for all the treatment
groups. Body weight was significantly higher for
the control rats than for the other groups at day
20 (p<0.05 vs. PAN, PAN+CsA). Serum creatinineBeom Seok Kim, et al. 144
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levels for the PAN-administered animals were
significantly higher than those for the normal
control animals (0.46 ± 0.08 mg/dL vs. 0.40 ±0.07
mg/dL, p<0.01). Serum creatinine levels were
significantly higher in the PAN+CsA group than
in the PAN group on day 18 (0.55 ± 0.10, p<0.01)
(Table 1).
Proteinuria
The normal control values for 24-hour urinary
protein in the rats used in this study did not
exceed 30 mg. Fig. 1 shows the 24-hour urinary
protein values for the experimental rats following
the injection of PAN. There was a gradual in-
crease of proteinuria for the PAN rats (n=6) as
compared to the control rats (n=6). This increase
was ameliorated by the CsA treatment. Eighteen
days after PAN administration, the mean value of
24-hour urinary protein excretion rose to 1021.9 ±
128.9 mg/day for the PAN group (p<0.01 vs.
control). The CsA treatment induced a significant
reduction in the proteinuria levels (556.4 ± 102.3
mg/day, p<0.01 vs. PAN).
Western blot
Fig. 2 shows the ZO-1 protein expression as es-
Table 1. Body Weight, 24 Hour Urinary Protein Excretion and Serum Creatinine Levels of the Three Groups on the
Days 0 and 18 after PAN Injection
Control (n=6) PAN (n=6) PAN+CsA (n=6)
Day of PAN injection
Body Weight (g)
Urine protein (mg/day)
Serum creatinine (mg/dL)
Day 20 after PAN injection
Body Weight (g)
Urine protein (mg/day)
Serum creatinine (mg/dL)
171.0 ± 6.0
15.5 ± 4.2
0.18 ± 0.03
294.2 ± 8.7
35.1 ± 5.4
0.40 ± 0.07
163.5 ± 5.1
11.3 ± 3.8
0.20 ± 0.05
228.6 ± 48.9*
1021.9 ± 128.9
0.46 ± 0.08
166.3 ± 5.7
12 ± 7.1
0.18 ± 0.04
220.4 ± 53.0*
556.4 ± 102.3
0.55 ± 0.10
PAN, Puromycin aminonucleoside treated rats; PAN+CsA, cyclosporin treated PAN.
*p<0.05 vs. Control, p<0.01 vs. Control, p<0.01 vs. PAN.
Fig. 1. 24 hour urine protein analysis of the three groups.
There was a gradual increase of proteinuria in PAN rats
(n=6) compared to Control rats (n=6). This increase was
significantly ameliorated by the cyclosporin treatment.
PAN, Puromycin aminonucleoside treated rats; PAN+CsA,
cyclosporin treated PAN. *p<0.01 vs. Control,
#p<0.01 vs.
PAN.
Fig. 2. Glomerular ZO-1 expression in the three groups
assessed by Western blot. The results are expressed as
relative changes in glomerular ZO-1 level. There was a
176% increase in glomerular ZO-1 expression in PAN rats
(n=6) compared to Control rats (n=6). This increase was
ameliorated by cyclosporin treatment. PAN, Puromycin
aminonucleoside treated rats; PAN+CsA, cyclosporin
treated PAN. *p<0.01 vs. Control,
#p<0.05 vs. PAN.Cyclosporin Reduced ZO-1 Expression in PAN Rats 145
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timated by the Western blot method in the con-
trol, PAN and PAN+CsA groups. Relying on in-
formation gleaned from previous research reports,
the 225-kD band was selected and quantified for
a statistical analysis.
18 We found that there was a
significant increase of ZO-1 proyein expression in
PAN group (176%, p<0.01), and this increase was
ameliorated by the CsA treatment (71.1%, p<
0.05).
Immunohistochemistry
In the normal glomeruli, ZO-1 showed an epi-
thelial staining along the peripheral capillary
loops of the glomeruli. PAN increased the ex-
pression of ZO-1, and CsA had the opposite effect
(Fig. 3). Fig. 4 shows the semiquantitative mea-
surement of the staining.
DISCUSSION
Passage of plasma proteins across the glomeru-
lar basement membrane is believed to be normally
restricted by a charge-selective barrier and a size-
selective barrier.
27,28 although much of investiga-
tions have revealed that the defect in minimal-
change glomerulopathy results mainly from a loss
of charge selectivity,
29 several recent studies have
shown that slit diaphragms located between the
foot processes may play a critical role as barriers
to retain macromolecules.
6-10
This study showed that the proteinuria induced
by PAN was reduced by the CsA treatment, and
these changes were accompanied by the change of
ZO-1 protein expression in the glomeruli. PAN
induced nephrosis is a well-described model of
human idiopathic nephrotic syndrome
30 and the
glomerular morphologic changes seen in rats with
PAN nephrosis closely resemble those in human
minimal change nephrotic syndrome (MCNS). In
addition, PAN targets the podocytes, inducing a
Fig. 4. Semiquantitative immunohistochemical staining
score of ZO-1 in the control, PAN and CsA treated PAN
rats. Expression of ZO-1 in PAN glomerulus was in-
creased as compared to that of control, and this increase
was ameliorated by the cyclosporin treatment. PAN, Puro-
mycin aminonucleoside treated rats; PAN+CsA, cyclospo-
rin treated PAN, *p<0.01 vs. Control,
#p<0.05 vs. PAN.
Fig. 3. Immunohistochemical staining of ZO-1 in the control, PAN and CsA treated PAN rats. Expression of ZO-1 in PAN
glomerulus was increased as compared to that of Control. This increase was ameliorated by the cyclosporin treatment. PAN,
Puromycin aminonucleoside treated rats; PAN+CsA, cyclosporin treated PAN.Beom Seok Kim, et al. 146
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focal segmental glomerulosclerosis (FSGS).
31
However, the precise mechanisms of this PAN-
induced proteinuria are not well understood. In
the normal rat, the foot processes of podocytes are
kept wide open to facilitate the passage of the
glomerular filtrate, and they are held together by
tenuous slit diaphragms that bridge the filtration
slits. In contrast, in the PAN nephrosis rat, the
foot processes are reduced in number, the filtra-
tion slits are greatly narrowed and the slit dia-
phragms are displaced by occluding-type junc-
tions.
18 The major morphologic changes in PAN
nephrosis are seen as the effacement of the foot
processes of glomerular visceral epithelial cells, or
the podocytes.
30,32,33 The podocyte is a complex
cell with many remarkable structural and func-
tional properties. As PAN treatment leads to pro-
found changes in the well-organized cytoskeleton
of podocytes,
30 this process warrants a detailed
molecular analysis of the diseased podocytes.
Recent studies have shown remarkable changes
both in nephrin and in the proteins directly
associating with it.
26 ZO-1 protein is a component
of the slit diaphragm that seems to play a pivotal
role in maintaining the permeable-selective prop-
erties of the glomerular capillary wall.
18 ZO-1
protein has been reported in several studies as
one of the proteins that may be associated with
the development of proteinuria.
10,17,18 Reiser et al.
15
have demonstrated that the slit diaphragm re-
presents an adherens junction that is composed of
P-cadherin, ZO-1 and catenin.
Here in our study, we observed an up-regula-
tion of ZO-1 protein in PAN nephrosis by the use
of a Western blot technique and subsequent im-
munohistochemistry. From the immunohistoche-
mical findings, we found that ZO-1 expression
increased along the capillary wall side. Yet in our
current study, we could not clarify the precise role
of increased ZO-1, but it may be due to an adap-
tive response of the podocytes to maintain the
filtration barrier during the PAN challenge. One
possible explanation for this result is that ZO-1
protein might contribute in creating newly formed
cell-to-cell junctions between the podocytes as a
compensatory mechanism. Although Kurihara et
al.
18 showed an altered distribution of ZO-1 pro-
tein in PAN nephrosis, they did not demonstrate
the quantitative analysis of ZO-1 protein. One
major difference between our study and the pre-
vious one was the PAN treated time18. We treated
PAN for almost 3 weeks, but previous data were
obtained in much shorter experimental time. It
may be possible that ZO-1 change in PAN treated
glomeruli varies with time course.
Effacement of the foot processes, which is asso-
ciated with proteinuria in many renal diseases, is
reparable when appropriate therapeutic approa-
ches are successfully employed. However, the
specific regulators for this regeneration process
are also unknown. Although recent studies have
suggested the importance of the proteins consti-
tuting the slit diaphragm in developing proteinu-
ria,
26,34 there has been no data about the effects of
CsA on the slit diaphragm associated protein in
the nephrotic models. We found that CsA dimin-
ished both the ZO-1 protein expression of the
glomeruli and the proteinuria in PAN nephrosis.
The previous clinical studies have suggested that
CsA may have a beneficial effect in reducing pro-
teinuria in MCNS and the nephrotic syndrome
that is associated with FSGS.
35-39 The precise
mechanism by which CsA reduces proteinuria in
nephrotic syndrome and PAN nephrosis is largely
unknown. Bustos et al.
40 have shown that CsA
modulates the glomerular production of inflam-
matory mediators in the PAN model. Wangs et
al.
41 reported that CsA helped to recover the
diminished level of glomerular superoxide dis-
mutase and also the level of catalase in PAN ne-
phrosis. The amelioration of ZO-1 changes shown
in the current study suggested that CsA had an
effect on the proteins that help to make up the slit
diaphragm, and so CsA might decrease proteinu-
ria in the nephrotic models. But it is somewhat
unclear whether the change of ZO-1 protein has
any direct relationship with proteinuria or not.
CsA usually takes effect by an immunologic
mechanism, but several reports have demon-
strated the effect of CsA on non-immunologic
diseases such as Alport's syndrome and diabetic
glomerulosclerosis.
42,43 Jameson et al.
23 studied fil-
tration by subcutaneously injecting isolated rat
glomeruli with either saline or CsA at a dose of
30 mg/kg/day for 2 - 3 weeks, and they demon-
strated a pharmacologic effect of CsA on the glo-
merular filtration barrier in an experimental situa-
tion where no hemodynamic phenomenon couldCyclosporin Reduced ZO-1 Expression in PAN Rats 147
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be at work. In a passive model of anti-GBM ne-
phritis in the mouse, Berden et al.
44 compared the
effect of CsA on proteinuria and on GFR with that
of a solvent. CsA was noted by Berdan and
colleagues to reduced protein excretion and the
GFR. To dissociate the effect of CsA on glomeru-
lar permeability to the proteins and the hemo-
dynamic effect of the drug, the experiment was
repeated before and after with the addition of
phenoxybenzamine, a solvent which abolished
glomerular vasoconstriction. Although both ex-
perimental conditions had similar GFRs, the albu-
minuria was significantly less with using CsA.
Berden et al concluded that the antiproteinuric
effect of CsA was essentially due to the reduced
glomerular basement membrane permeability to
albumin, and it was not due to a hemodynamic
phenomenon. Zietse et al.
24 studied 20 patients
with nephrotic syndrome, and CsA induced com-
plete remission in the patients with MCNS, with
no consistent change being noted for the GFR. In
the six patients with idiopathic membranous glo-
merulonephropathy (IMGN), CsA induced partial
remission and the GFR was unchanged. Infusion
of dextrans showed a decreased clearance for
molecules of 50 - 58 A. Conversely, membranopro-
liferative glomerulonephritis (MPGN) and FSGS
proteinuria did not respond to CsA despite a fall
in GFR and decrease of a renal plasma flow of 20
to 33% respectively. The authors concluded that in
MCNS, CsA had decreased the proteinuria through
an increase of charge selectivity. In IMGN, CsA
seemed to decrease proteinuria by an increase of
pore size selectivity. So, the possible mechanism
of CsA on PAN nephrosis could take place both
ways. Further studies should be considered to
unveil the precise mechanism of CsA on PAN
nephrosis.
In conclusion, CsA treatment significantly re-
duced proteinuria and diminished the glomerular
ZO-1 expression in a rat model PAN nephrosis.
These findings suggest the potential role of slit
diaphragm associated proteins in the development
of the nephrotic syndrome, and CsA decreased
the proteinuria probably by a direct action on the
expression of these proteins in the podocyte.
Further investigations are needed to clarify the
role of slit diaphragm associated proteins in the
development of PAN nephrosis.
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